Gevo (NASDAQ:GEVO) and CTD (OTCMKTS:CTDH) are both small-cap oils/energy companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.
Earnings and Valuation
This table compares Gevo and CTD’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Gevo||$27.54 million||0.90||-$24.63 million||($32.20)||-0.10|
|CTD||$1.23 million||49.71||-$3.83 million||N/A||N/A|
Risk and Volatility
Gevo has a beta of 2.65, meaning that its share price is 165% more volatile than the S&P 500. Comparatively, CTD has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500.
This table compares Gevo and CTD’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current recommendations and price targets for Gevo and CTD, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Gevo currently has a consensus price target of $240.00, suggesting a potential upside of 7,692.21%. Given Gevo’s higher probable upside, research analysts plainly believe Gevo is more favorable than CTD.
Institutional and Insider Ownership
5.0% of Gevo shares are owned by institutional investors. 0.1% of Gevo shares are owned by company insiders. Comparatively, 46.0% of CTD shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Gevo beats CTD on 8 of the 11 factors compared between the two stocks.
Gevo, Inc., a renewable chemicals and biofuels company, focuses on the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks in the United States. It operates through two segments, Gevo, Inc. and Gevo Development/Agri-Energy. The company engages in the research and development, and production of isobutanol; development of its proprietary biocatalysts; production and sale of biojet fuel; and retrofit process of chemicals and biofuels. It is also involved in the production of ethanol, isobutanol, and related products. In addition, the company produces and separates its renewable isobutanol through the Gevo Integrated Fermentation Technology platform. The company was formerly known as Methanotech, Inc. and changed its name to Gevo, Inc. in March 2006. Gevo, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.
CTD Holdings, Inc., a biotechnology company, develops cyclodextrin-based products for the treatment of diseases. The company's lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Neimann-Pick Type C disease. The company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. CTD Holdings, Inc. was founded in 1990 and is based in Gainesville, Florida.
Receive News & Ratings for Gevo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gevo and related companies with MarketBeat.com's FREE daily email newsletter.